FORM 4	4
--------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

_ *									
1. Name and Address of Reporting Person [*] Clark Mitchall G.				ling Symt [RA]	ool	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900				nth/Day/Y	(ear)	X_Officer (give title below) Other (specify below) EVP & Chief R & QA Officer			
(Street) SOUTH SAN FRANCISCO, CA 94080				ed(Month/D	ay/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
2. Transaction Date (Month/Day/Year)	Execution Date, if any	Code (Instr. 8)	-	(A) or D (Instr. 3,	isposed 4 and 5 (A) or	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct (D)	Beneficial Ownership
02/15/2018		М		7,211	A		187,124	D	
02/15/2018		F <mark>(2)</mark>		3,604	D	\$ 47.05	183,520	D	
)	(Middle) (ARD, SUITE 900) D, CA 94080) (Zip) 2. Transaction Date (Month/Day/Year) 02/15/2018	Atara Biotherape (Middle) (ARD, SUITE 900 2/15/2018 (Zip) (Zip) 2. Transaction Date (Month/Day/Year) 02/15/2018 2. Transaction Date (Month/Day/Year) 02/15/2018	Atara Biotherapeutics, Inc. (Middle) (ARD, SUITE 900 3. Date of Earliest Transaction 02/15/2018 (ARD, SUITE 900 4. If Amendment, Date Origina (D) 4. If Amendment, Date Origina (Zip) Table I - Non 2. Transaction Date (Month/Day/Year) 3. Transact Code (Instr. 8) (Month/Day/Year) Code 02/15/2018 M	Atara Biotherapeutics, Inc. [AT (Middle) 3. Date of Earliest Transaction (Mor (ZaRD, SUITE 900 02/15/2018 (Zip) 4. If Amendment, Date Original File (Zip) Table I - Non-Der 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 02/15/2018 M	Atara Biotherapeutics, Inc. [ATRA] (Middle) 3. Date of Earliest Transaction (Month/Day/Y 02/15/2018 (Middle) 3. Date of Earliest Transaction (Month/Day/Y 02/15/2018 (Middle) 4. If Amendment, Date Original Filed(Month/D Date (Zip) Table I - Non-Derivative S 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securi (A) or D (Instr. 3, Code 02/15/2018 M 7,211	Atara Biotherapeutics, Inc. [ATRA] (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (ARD, SUITE 900 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) (Atara Biotherapeutics, Inc. [ATRA] (Month/Day/Year) 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) (Atara Biotherapeutics, Inc. [ATRA] (ARD, SUITE 900 2/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (Atara Biotherapeutics, Inc. [ATRA] (Month/Day/Year) (Atara Biotherapeutics, Inc. [ATRA] (Atara Biotherapeutics, Inc. [Atara, Inc. [Atara] (Month/Day/Year) (A) or Disposed (Instr. 8) (Instr. 8) (Instr. 8) (A) or Code (A) or (D) (A) or (D) <td< td=""><td>Atara Biotherapeutics, Inc. [ATRA] (Middle) (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (Middle) (2/15/2018 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (Middle) (2/15/2018 (Zip) (At a Biotherapeutics, Inc. [ATRA] (At a Giotherapeutics, Inc. [ATRA] (At a Giotherapeutics, Inc. [ATRA] (Month/Day/Year) (A. Deemed (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A mount (A) or (D) (A mount (A) or (D) (A mount (A) or (I) (A mount (A) or (I) <tr< td=""><td>Atara Biotherapeutics, Inc. [ATRA] (Check all appli</td><td>Atara Biotherapeutics, Inc. [ATRA] (Check all applicable) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) EVP & Chief R & QA Officer (O) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2.A. Deemed Date 3. Transaction (Month/Day/Year) A. Deemed (Month/Day/Year) 3. Transaction (A) or Date (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3 and 4) (D2/15/2018 M 7,211 02/15/2018 M 7,211</td></tr<></td></td<>	Atara Biotherapeutics, Inc. [ATRA] (Middle) (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (Middle) (2/15/2018 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2018 (Atara Biotherapeutics, Inc. [ATRA] (Middle) (2/15/2018 (Zip) (At a Biotherapeutics, Inc. [ATRA] (At a Giotherapeutics, Inc. [ATRA] (At a Giotherapeutics, Inc. [ATRA] (Month/Day/Year) (A. Deemed (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A mount (A) or (D) (A mount (A) or (D) (A mount (A) or (I) (A mount (A) or (I) <tr< td=""><td>Atara Biotherapeutics, Inc. [ATRA] (Check all appli</td><td>Atara Biotherapeutics, Inc. [ATRA] (Check all applicable) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) EVP & Chief R & QA Officer (O) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2.A. Deemed Date 3. Transaction (Month/Day/Year) A. Deemed (Month/Day/Year) 3. Transaction (A) or Date (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3 and 4) (D2/15/2018 M 7,211 02/15/2018 M 7,211</td></tr<>	Atara Biotherapeutics, Inc. [ATRA] (Check all appli	Atara Biotherapeutics, Inc. [ATRA] (Check all applicable) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner (ARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) EVP & Chief R & QA Officer (O) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2.A. Deemed Date 3. Transaction (Month/Day/Year) A. Deemed (Month/Day/Year) 3. Transaction (A) or Date (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3 and 4) (D2/15/2018 M 7,211 02/15/2018 M 7,211

 Persons who respond to the collection of information
 SEC 1474 (9-02)

 contained in this form are not required to respond unless the form displays a currently valid OMB control number.
 SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. N	Jumber	6. Date Exer	rcisable	7. Title and	l	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	of		and Expirati	on Date	Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Der	ivative	(Month/Day	/Year)	Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Sec	urities			Securities		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acc	quired			(Instr. 3 and	d 4)		Owned	Security:	(Instr. 4)
	Security					(A)	or						Following	Direct (D)	
							posed						· · · · · ·	or Indirect	
						of (Transaction(s)	· · /	
							str. 3, 4,						(Instr. 4)	(Instr. 4)	
						and	5)								
											Amount				
								Date	Expiration		or				
								Exercisable	-	Title	Number				
								Excicisable	Date		of				
				Code	V	(A)	(D)				Shares				
Restricted										~					
Stock	(3)	02/15/2018		М			7,211	<u>(4)</u>	(5)	Common	7,211	\$ 0	4,808	D	
Units		02/10/2010		1/1			,,211			Stock	,,,11	ψŪ	1,000	D	
Units															

Reporting Owners

Demostin - Orman Nama (Addama	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Clark Mitchall G. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080			EVP & Chief R & QA Officer					

Signatures

/s/ David Tucker, Attorney-in-Fact for Mitchall G. Clark	02/20/2018	
**Signature of Reporting Person	Date	

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares issued upon settlement of vested restricted stock units ("RSUs").

(2) Shares withheld to cover tax obligation from settlement of vested restricted stock units.

(3) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.

The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the (4) RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares nonthly thereafter, subject to the holder's continuous service through each such date. (5) The earlier of (i) March 27, 2021 or (ii) the recepient's termination date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.